Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzyme Research
New enzyme research from University of Pennsylvania, Medical Department outlined
March 3rd, 2009
In this recently published article, scientists in the United States conducted a study "To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5'-DFUR or Xeloda (R)), in the treatment of human head and neck squamous cell carcinoma (HNSCC). Quantitative reverse-transcriptase polymerase chain reaction was used to determine the TP and DPD expression levels in different HNSCC cell lines." "The TP to DPD ratio was calculated and compared to the relative chemosensitivity between cell lines...
Source: Cancer Weekly (2009-03-03)
|
